Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)

N Harbeck; D Wrobel; M Zaiss; D Guth; A Distelrath; J Terhaag; A Lorenz; R Bartsch; U Breitenstein; M Schwitter; M Balic; C Jackisch; V Muller; Gabriel Rinnerthaler; M Schmidt; K Zaman; T Schinkothe; D Luftner

doi:10.1016/j.annonc.2022.03.091

Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)

N Harbeck, D Wrobel, M Zaiss, D Guth, A Distelrath, J Terhaag, A Lorenz, R Bartsch, U Breitenstein, M Schwitter, M Balic, C Jackisch, V Muller, Gabriel Rinnerthaler, M Schmidt, K Zaman, T Schinkothe, D Luftner

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

2 Citations (Web of Science)

Original language	English
Pages (from-to)	S157-S157
Journal	ANNALS OF ONCOLOGY
Volume	33
DOIs	https://doi.org/10.1016/j.annonc.2022.03.091
Publication status	Published - 2022

Access to Document

10.1016/j.annonc.2022.03.091

Cite this

Harbeck, N., Wrobel, D., Zaiss, M., Guth, D., Distelrath, A., Terhaag, J., Lorenz, A., Bartsch, R., Breitenstein, U., Schwitter, M., Balic, M., Jackisch, C., Muller, V., Rinnerthaler, G., Schmidt, M., Zaman, K., Schinkothe, T., & Luftner, D. (2022). Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC). ANNALS OF ONCOLOGY , 33, S157-S157. https://doi.org/10.1016/j.annonc.2022.03.091

Harbeck, N ; Wrobel, D ; Zaiss, M et al. / Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC). In: ANNALS OF ONCOLOGY 2022 ; Vol. 33. pp. S157-S157.

@article{a1f61bd886d84b5abf4a57c1b0bc8763,

title = "Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)",

author = "N Harbeck and D Wrobel and M Zaiss and D Guth and A Distelrath and J Terhaag and A Lorenz and R Bartsch and U Breitenstein and M Schwitter and M Balic and C Jackisch and V Muller and Gabriel Rinnerthaler and M Schmidt and K Zaman and T Schinkothe and D Luftner",

year = "2022",

doi = "10.1016/j.annonc.2022.03.091",

language = "English",

volume = "33",

pages = "S157--S157",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

}

Harbeck, N, Wrobel, D, Zaiss, M, Guth, D, Distelrath, A, Terhaag, J, Lorenz, A, Bartsch, R, Breitenstein, U, Schwitter, M, Balic, M, Jackisch, C, Muller, V, Rinnerthaler, G, Schmidt, M, Zaman, K, Schinkothe, T & Luftner, D 2022, 'Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)', ANNALS OF ONCOLOGY , vol. 33, pp. S157-S157. https://doi.org/10.1016/j.annonc.2022.03.091

Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC). / Harbeck, N; Wrobel, D; Zaiss, M et al.
In: ANNALS OF ONCOLOGY , Vol. 33, 2022, p. S157-S157.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)

AU - Harbeck, N

AU - Wrobel, D

AU - Zaiss, M

AU - Guth, D

AU - Distelrath, A

AU - Terhaag, J

AU - Lorenz, A

AU - Bartsch, R

AU - Breitenstein, U

AU - Schwitter, M

AU - Balic, M

AU - Jackisch, C

AU - Muller, V

AU - Rinnerthaler, Gabriel

AU - Schmidt, M

AU - Zaman, K

AU - Schinkothe, T

AU - Luftner, D

PY - 2022

Y1 - 2022

U2 - 10.1016/j.annonc.2022.03.091

DO - 10.1016/j.annonc.2022.03.091

M3 - Abstract (Journal)

SN - 0923-7534

VL - 33

SP - S157-S157

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

ER -

Harbeck N, Wrobel D, Zaiss M, Guth D, Distelrath A, Terhaag J et al. Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC). ANNALS OF ONCOLOGY . 2022;33:S157-S157. doi: 10.1016/j.annonc.2022.03.091